Drugs / Radium-1 TCR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03431311 | Mar 2018 → Jun 2019 | colorectal cancer | Oslo University Hospital | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Radium-1 TCR | “Following 12 escalating doses of autologous T cells electroporated with in-vitro-transcribed Radium-1 TCR mRNA” PMID 38582964 ↗ Apr 2024 |
| Action | Deplete | “We confirmed cytotoxicity of transfected Radium-1 T cells against target cells” PMID 38582964 ↗ Apr 2024 |
| Modality | Cell therapy | “The patients will be given adoptive cell therapy (ACT) with Radium-1 TCR+ T cells” NCT03431311 ↗ |
| Route | Intravenous | “The ACT will be administered as two intravenous (i.v.) injections of GMP TCR T cells per week for 6 weeks.” NCT03431311 ↗ |